Inovio Halts Head And Neck Cancer Trials On Safety Concerns
This article was originally published in The Gray Sheet
Inovio Biomedical prematurely halted a pivotal study investigating its tumor ablation technology in head and neck cancer June 5 after an independent data monitoring committee raised concerns about adverse events
You may also be interested in...
Genetronics Biomedical is in talks with FDA to pursue clinical development of the MedPulsor tumor ablation system through a device regulatory route
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.